ArticleAntimicrobial agents and chemotherapy2021
Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 51 citations in OpenAlex.
- Towards Antimicrobial Formulations of Repurposed Drugs and Cationic Surfactants: Efficacy, Cytotoxicity on Human Cell Lines, and Ecotoxicity in Aquatic Models.Antibiotics (Basel, Switzerland) · 2026Article
- The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Biological characterization and genomic analysis of Kpp-61, a lytic bacteriophage against K1-type Klebsiella pneumoniae.Archives of virology · 2026Article
- Repurposing antibiotics: A dual-action approach against bacteria-induced cancer.Cancer pathogenesis and therapy · 2025Review
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Combination of mitomycin C and low-dose metronidazole synergistically againstAntimicrobial agents and chemotherapy · 2025Article
- Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations.The Journal of antimicrobial chemotherapy · 2025Article
- Combined Forces Against Bacteria: Phages and Antibiotics.Health science reports · 2025Article
- StudiesAntimicrobial agents and chemotherapy · 2025Article
- Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States.Antibiotics (Basel, Switzerland) · 2025Review
- Antibacterial compounds against non-growing and intracellular bacteria.npj antimicrobials and resistance · 2025Article
- Combination therapy delays antimicrobial resistance after adaptive laboratory evolution ofAntimicrobial agents and chemotherapy · 2025Article
- Phage-antibiotic combinations againstFrontiers in microbiology · 2025Article
- Eradication ofACS infectious diseases · 2024Article
- Mitomycin C as an Anti-Persister Strategy againstAntibiotics (Basel, Switzerland) · 2024Article
- The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.Virology journal · 2024Review
- Phages produce persisters.Microbial biotechnology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting imipenem-resistant and persister strains of K. pneumoniae by repurposing the anticancer drug mitomycin C as an antimicrobial agent and by combining the drug and the conventional antibiotic imipenem with the lytic phage vB_KpnM-VAC13. Several clinical K. pneumoniae isolates were characterized, and an imipenem-resistant isolate (harboring OXA-245 β-lactamase) and a persister isolate were selected for study. The mitomycin C and imipenem MICs for both isolates were determined by the broth microdilution method. Time-kill curve data were obtained by optical density at 600 nm (OD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.